Inactive Instrument

Highlights 4d Pharma PLC London S.E.

Equities

GB00BJL5BR07

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil	23-02-03	AN
4D pharma plc Updates Results from Renal Cell Carcinoma Cohort	23-02-02	CI
4D pharma's Blautix Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics	22-11-18	CI
4D pharma Remains Suspended from Trading on London's AIM	22-09-29	MT
4D pharma plc Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder	22-08-24	CI
4D Pharma plc Is Temporarily Pausing Recruitment into Ongoing Clinical Trials	22-07-05	CI
4D Pharma Says Nasdaq to Delist Shares from Exchange	22-06-29	MT
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology Annual Meeting	22-05-26	CI
4D pharma : Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 - Form 6-K	22-04-04	PU
4D pharma : Annual Report and Account for the year ended 31 December 2021	22-04-01	PU
4D pharma plc Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022	22-03-31	BU
4D pharma plc Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and Keytruda® (Pembrolizumab) for the Treatment of Renal Cell Carcinoma	22-03-23	CI
4D Pharma plc Announces That U.S. Food and Drug Administration Cleared Investigational New Drug Applications for Mrx0005 and Mrx0029 for Treatment of Parkinson's Disease	22-02-22	CI
4D pharma : to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants - Form 6-K	22-02-18	PU
4D pharma plc Announces Additional Positive Data from Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma	22-01-27	CI
4D pharma plc Announces Positive Topline Results from Part A of I/II Clinical Trial of MRx-4DP0004	21-12-13	CI
4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021	21-12-09	CI
4D pharma : Consolidated Financial Statements (Form 6-K)	21-10-01	PU
4D pharma : (“4D”, “4D Pharma” or “the Company”) (Form 6-K)	21-09-30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 4d Pharma PLC London S.E.

Equities

GB00BJL5BR07

Highlights

Filters